BioRestorative Therapies, Inc. - Common Stock (NQ:BRTX)

2.140 -0.130 (-5.73%)

Delayed Quote Updated: 3:59 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioRestorative Therapies, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

EXCLUSIVE: Data Monitoring Committee Allows BioRestorative's Chronic Lumbar Disc Disease Study To Continue Unchanged ↗

June 27, 2023

BioRestorative Therapies Inc (NASDAQ: BRTX) has announced that the independent Data Safety Monitoring Board (DSMB), overseeing the company's ongoing Phase 2 trial to treat chronic lumbar disc disease,...

Via Benzinga

Why Carnival Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

June 26, 2023

Gainers Benitec Biopharma Inc. (NASDAQ: BNTC) climbed 104% to $0.4050 after the company announced it received FDA clearance of the IND for BB-301 for the treatment of Oculopharyngeal Muscular...

Via Benzinga

BioResorative CEO is Featured in An Interview With SmallCaps Daily

June 26, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Why BioRestorative Therapies Stock Is Climbing Higher Today ↗

March 02, 2023

BioRestorative Therapies, Inc.

Via Benzinga

Metabolic Syndrome: The Silent Epidemic On The Rise And How BioRestorative Therapies Inc. Is Helping Fight It

June 15, 2023

Via ACCESSWIRE

Metabolic Syndrome: The Silent Epidemic On The Rise And How BioRestorative Therapies Inc. Is Helping Fight It ↗

June 14, 2023

Once a lesser-known health condition, now a problem crippling millions of people around the world: metabolic syndrome is unfortunately on the rise.

Via Benzinga

EXCLUSIVE: BioRestorative Completes Dosing In Safety Cohort Of Chronic Lower Back Pain Trial ↗

June 12, 2023

BioRestorative Therapies Inc (NASDAQ: BRTX) announced that the final subject in its BRTX-100 Phase 2 trial safety cohort has been dosed.

Via Benzinga

EXCLUSIVE: BioRestorative Therapies Wins License from New York State Department of Health To Act As Tissue Bank for Mesenchymal Stem Cell Processing ↗

May 31, 2023

BioRestorative Therapies, Inc (NASDAQ: BRTX), bagged a license from the New York State Department of Health to act as a tissue bank for processing

Via Benzinga

A Cure For Back Pain? Phase II Clinical Trials Begin For Promising Drug Candidate ↗

May 25, 2023

Dr. Jason Lipetz, MD, Physiatrist & Head of Spine Medicine at Northwell Health, was recently interviewed by Benzinga. Dr. Lipetz is currently assisting BioRestorative Therapies, Inc (NASDAQ: BRTX) in...

Via Benzinga

EXCLUSIVE: BioRestorative Therapies' ThermoStem For Metabolic Disorders Expected To Receive Fourth Japanese Patent ↗

May 15, 2023

BioRestorative Therapies Inc (NASDAQ: BRTX) has announced that the Japanese Patent and Trademark Office has issued a notice of allowance for a patent application related to its metabolic ThermoStem...

Via Benzinga

A New Era In Regenerative Medicine? BioRestorative Therapies (NASDAQ:BRTX) Reports Leading The Expansion Of The Adipose-Derived Stem Cell Therapy Market

May 12, 2023

Via ACCESSWIRE

EXCLUSIVE: BioRestorative Therapies & Northwell Health Ink Trial Pact For Chronic Lower Back Pain Study ↗

May 08, 2023

BioRestorative Therapies Inc (NASDAQ: BRTX) has signed a clinical trial agreement with Northwell Health and Northwell's Feinstein Institutes for Medical Research to participate in the company's Phase 2...

Via Benzinga

BioRestorative Therapies, Inc. (NASDAQ: BRTX) Featured in Coverage of the Inaugural EF Hutton Global Conference

May 02, 2023

Via Investor Brand Network

EXCLUSIVE: BioRestorative Concludes Enrollment For Safety Run-In Component Of Cell Therapy Study For Chronic Lower Back Pain ↗

April 24, 2023

BioRestorative Therapies Inc (NASDAQ: BRTX) has completed enrollment for the safety run-in component of its Phase 2 study of BRTX-100 targeting patients suffering from chronic lumbar disc disease...

Via Benzinga

BioRestorative Therapies (NASDAQ: BRTX) Is Targeting The Global Obesity Epidemic With Its Recent IP Portfolio Expansion

March 31, 2023

By Julian Richard, Benzinga

Via TheNewswire.com

Topics Intellectual Property

BioRestorative Therapies (NASDAQ: BRTX) Is Targeting The Global Obesity Epidemic With Its Recent IP Portfolio Expansion

March 31, 2023

BioRestorative Therapies (NASDAQ: BRTX) Is Targeting The Global Obesity Epidemic With Its Recent IP Portfolio Expansion

Via News Direct

Topics Intellectual Property

BioRestorative Therapies (NASDAQ: BRTX) Is Targeting The Global Obesity Epidemic With Its Recent IP Portfolio Expansion ↗

March 30, 2023

BioRestorative Therapies Inc (NASDAQ: BRTX) is expanding its ThermoStem® intellectual property portfolio for treatments targeting obesity, diabetes and other indications related to metabolic syndrome...

Via Benzinga

What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years? ↗

March 21, 2023

Successful Autologous Cell-Based Therapies

Via Benzinga

EXCLUSIVE: BioRestorative Seeks Expanded FDA Approval For BRTX-100 Clinical Application, Engages Advisory Firm ↗

March 13, 2023

BioRestorative Therapies Inc (NASDAQ: BRTX) has entered into an agreement with Bruder Consulting & Venture Group, a full-service strategic advisory, to assist the company in seeking FDA approval for...

Via Benzinga

BRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome

March 09, 2023

By Julian Richard, Benzinga

Via TheNewswire.com

BRTX's ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome ↗

March 08, 2023

Metabolism is the chemical process whereby the body produces energy from food. By breaking down carbohydrates and fats into sugars, the cells access fuel that can be used or stored via the liver or...

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

March 06, 2023

Via Benzinga

BioMedNewsBreaks – BioRestorative Therapies Inc. (NASDAQ: BRTX) Receives Notice of Third US Patent Related to ThermoStem IP

March 03, 2023

Via Investor Brand Network

Topics Intellectual Property

Dow Jumps Over 300 Points; Best Buy Profit Beats Views ↗

March 02, 2023

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 300 points on Thursday. The Dow traded up 0.97% to 32,978.95 while the NASDAQ rose 0.59% to 11,446.55. The S&P...

Via Benzinga

Why Cano Health Shares Are Trading Lower By Around 23%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

March 02, 2023

Gainers Exela Technologies, Inc. (NASDAQ: XELA) shares surged 45% to $0.0701 after the company announced $51 million of new funding, amendment increases existing securitization facility to $185 million...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

March 02, 2023

Via Benzinga

Dow Rises 100 Points; Macy's Posts Upbeat Earnings ↗

March 02, 2023

U.S. stocks traded mixed midway through trading, with the Dow Jones gaining around 100 points on Thursday. The Dow traded up 0.31% to 32,764.50 while the NASDAQ fell 0.49% to 11,324.28. The S&P 500...

Via Benzinga

BioRestorative Therapeutics (BRTX) Stock Soars 40% on Patent News ↗

March 02, 2023

Could more patents translate to more revenue for BioRestorative Therapeutics? It's a question that BRTX stock traders are considering now.

Via InvestorPlace

Wall Street Mixed At Open; US Weekly Jobless Claims Decline ↗

March 02, 2023

U.S. stocks traded mixed this morning, with the Dow Jones gaining around 80 points on Thursday. Following the market opening Thursday, the Dow traded up 0.24% to 32,740.88 while the NASDAQ fell 0.58%...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

March 02, 2023

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.